PrimeRFP SCOUT · Federal Contract Recompete Brief

36C24526N0555Patient medication of oxercate .002% for — Dompe U.S. Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Apr 30, 2026 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

245-Network Contract Office 5 (36C245)

Awarding office

Dompe U.S. Inc

Recipient

Apr 30, 2026

PoP end

$166K

Obligated

$166K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Dompe U.S. Inc — $90

Contract facts

Federal

Contract number36C24526N0555

Also listed as36C245-26-N-0555

Also listed as36F79720D0017-36C24526N0555

Agency245-Network Contract Office 5 (36C245)

Awarding office245-Network Contract Office 5 (36C245)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentDompe U.S. Inc

CAGE89P46

UEIECCDSKQAN2J3

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79720D0017

Place of performanceMEMPHIS TN

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startApr 28, 2026

PoP end (current)Apr 30, 2026

PoP end (w/ options)May 29, 2026

Obligated$166K

Current value$166K

Potential value$166K

PATIENT MEDICATION OF OXERCATE .002% FOR DIRECT SHIPMENT TO THE PATIENTS HOME. is a federal award for 245-Network Contract Office 5 (36C245) held by Dompe U.S. Inc. Estimated value $166K ($166K obligated). Current period of performance ends Apr 30, 2026 (potential May 29, 2026). Last award drew 1 bidder. Place of performance: MEMPHIS TN.

PATIENT MEDICATION OF OXERCATE .002% FOR DIRECT SHIPMENT TO THE PATIENTS HOME.

Recompete timing

Public

● Past PoP end (114 days ago)

Current PoP ended Apr 30, 2026 (114 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C24526N0555?

36C24526N0555 (Patient medication of oxercate .002% for) is a 245-Network Contract Office 5 (36C245) award with a potential value of $166K, currently held by Dompe U.S. Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C245-26-N-0555?

36C245-26-N-0555 is the dashed form of PIID 36C24526N0555 (Patient medication of oxercate .002% for), held by Dompe U.S. Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C24526N0555?

245-Network Contract Office 5 (36C245) awarded 36C24526N0555 to Dompe U.S. Inc (potential $166K).

Who is the incumbent on 36C24526N0555?

Dompe U.S. Inc is the incumbent. The current period of performance ends Apr 30, 2026.

When does Dompe U.S. Inc’s 36C24526N0555 come up for recompete?

SCOUT tracks a period-of-performance end of Apr 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Apr 30, 2026 · refreshed monthly